Mylan merger speculation
Executive Summary
Company denies rumors of potential merger. "Our board of directors...is of the view at this time that it would not serve the best interests of our shareholders to pursue a sale of the company," Mylan said June 28. Barr announced a merger with Duramed June 29 (1see related story, p. 21)
You may also be interested in...
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Par Aims To Add Branded Products After Merck KGaA Divests Equity Stake
Par is looking to add branded products to its portfolio as it seeks to join the top-tier independent generic drug companies after Merck KGaA divests its controlling interest in the firm.
Cenestin Sales Force Will Promote Seasonale After Barr/Duramed Merger
Barr's oral contraceptive Seasonale will be promoted by Duramed's Cenestin sales force following a merger between the two generic/brand drug companies.